Royce & Associates LP Sells 27,416 Shares of GeneDx Holdings Corp. $WGS

Posted by Brian Himes on May 28th, 2026

Royce & Associates LP reduced its stake in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 26.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 75,783 shares of the company’s stock after selling 27,416 shares during the period. Royce & Associates LP’s holdings in GeneDx were worth $9,856,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Arizona State Retirement System increased its position in shares of GeneDx by 2.1% during the fourth quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock worth $728,000 after acquiring an additional 113 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of GeneDx by 5.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after acquiring an additional 181 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after acquiring an additional 186 shares in the last quarter. Quarry LP increased its position in shares of GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after acquiring an additional 209 shares in the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of GeneDx by 9.2% during the fourth quarter. Pictet Asset Management Holding SA now owns 2,922 shares of the company’s stock worth $380,000 after acquiring an additional 246 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

GeneDx Trading Down 2.5%

Shares of WGS stock opened at $48.21 on Thursday. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The company has a 50-day simple moving average of $58.00 and a two-hundred day simple moving average of $96.72. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -17.99 and a beta of 2.06.

GeneDx (NASDAQ:WGS – Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. During the same period in the previous year, the company posted ($0.23) earnings per share. Research analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on WGS. Weiss Ratings raised shares of GeneDx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research report on Monday, February 23rd. Guggenheim decreased their target price on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 target price on shares of GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $130.00 target price (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

View Our Latest Stock Report on GeneDx

Insider Buying and Selling at GeneDx

In related news, Director Casdin Capital, Llc bought 185,000 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the purchase, the director directly owned 3,367,164 shares in the company, valued at $143,441,186.40. The trade was a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Keith A. Meister bought 533,758 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was bought at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the purchase, the director owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. The trade was a 16.53% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 2,225,941 shares of company stock worth $95,494,951 and have sold 104,028 shares worth $7,377,165. Corporate insiders own 29.60% of the company’s stock.

About GeneDx

(Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.